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patients with and without dose escalation, respectively, and CDN$29,504 and 
CDN$25,449 for infliximab in patients with and without dose escalation, 
respectively. CONCLUSIONS: Results of this RAMQ database analysis illustrate 
that, in a real-world setting and over a long period of time, CD patients treated 
with infliximab had a significantly higher proportion of dose escalation 
compared with patients treated with adalimumab. In both recommended and 
adjusted dosing, adalimumab demonstrated significant cost savings over 
infliximab.  
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OBJECTIVES: Assess the frequency and appropriateness of early repeated 
colonoscopy METHODS: Patients undergoing a colonoscopy in 2005 were identified 
using paid claims data from a nationwide privately insured population. Patients 
were screened to be between the ages of 50 and 64 years with at least one year 
continuous enrollment. Colonoscopies with evidence of positive results [e.g., paid 
claims for biopsy, fulguration, snare, etc.], or with evidence suggesting clinical 
indications three months prior to the screening were defined as non-screen tests. 
The cumulative probability of repeated screening colonoscopy was then 
documented and the related risk factors for appropriate and inappropriate repeat 
screening tests were assessed using survival analysis and Cox proportional hazard 
regression models. RESULTS: A total of 51,400 colonoscopies were identified from 
the paid claims in 2005 for patients age 50-64. The majority of these procedures 
were found to have either positive results [25,029 (48.7%)] or evidence of clinical 
indications for the procedure [17,842 (34.7%)]. Among 8,529 apparent screening 
colonoscopies with negative results, 8% had a repeated colonoscopy within six 
years, the majority of which were associated with evidence that the repeated test 
could be justified (78.7% with indications and 21.3% without indications). The initial 
regression analysis identified risk factors of repeated colonoscopy with indications 
including age over 55 (HR: 1.2; 95%CI: 1.0–1.5) and having at least one comorbidity 
(HR: 1.2; 95%CI: 1.0-1.5). The risk factors of repeated colonoscopy without 
indications include male (HR: 1.53; 95%CI: 1.07-2.20) and having at least one 
comorbidity (HR: 1.57; 95%CI: 1.04-2.31). CONCLUSIONS: The majority of all 
colonoscopies in 2005 were found not to be routine screening exams. The risk of a 
repeated screening colonoscopy within 6 years is low [8%]. Among these repeat 
procedures, the majority was done because of the existence of clinical indications.  
 
MUSCULAR-SKELETAL DISORDERS – Clinical Outcomes Studies 
 
PMS1  
FLUOROQUINOLONE-ASSOCIATED TENDON-RUPTURE: A SUMMARY OF 
REPORTS IN THE FOOD AND DRUG ADMINISTRATION'S (FDA'S) ADVERSE 
EVENT REPORTING SYSTEM  
Arabyat RM1, Garg V2, Raisch DW3, Bennett C4 
1University of New Mexico, Albuqurque, NM, USA, 2University of New Mexico, Albuquerque, 
NM, USA, 3University of New Mexico College of Pharmacy, Albuquerque, NM, USA, 4University 
of South Carolina, Columbia, SC, USA  
OBJECTIVES: Tendon rupture is associated with fluoroquinolones and listed in 
boxed warnings. We reviewed and summarized reports of tendon rupture 
associated with fluoroquinolones as reported in the FDA’s Adverse Event 
Reporting System (FAERS) through September 26, 2012. METHODS: We queried 
the FAERS for reports of tendon rupture involving each fluoroquinolone. Signal 
detection consisted of empiric Bayes geometric mean (EBGM), with 95% 
confidence intervals from initial marketing date for each drug. For a signal to be 
considered significant, minimum criteria are: reports of 3 or more cases, the low 
end of the 95% confidence interval must be 2.0 or greater. RESULTS: There were 
2539 tendon rupture cases. Most cases were reported with levofloxacin (61.25%) 
followed by ciprofloxacin (23.87%) and moxifloxacin (9.05%). Signal detection 
results for fluoroquinolones were: ciprofloxacin (EBGM=20.0, 95%CI=18.2-21.6), 
enoxacin (EBGM=13.2, 95%CI=4.2-29.7), gatifloxacin (EBGM=5.0, 95%CI=3.5-7.0), 
levofloxacin (EBGM=55.2, 95%CI=52.3-58.0), moxifloxacin (EBGM=13.3, 
95%CI=11.7-15.1), norfloxacin (EBGM=9.6, 95%CI=6.5-13.5), ofloxacin (EBGM=8.2, 
95%CI=6.3-10.2), gemifloxacin (EBGM=1.9, 95%CI=0.7-4.5), lomefloxacin 
(EBGM=2.3, 95%CI=0.94-5), and trovafloxacin (EBGM=0.3, 95%CI=0.08-1.1). FAERS 
event date timelines suggest lower risk of tendon rupture for gemifloxacin (n=5), 
lomefloxacin (n=5), and trovafloxan (n=1), with initial reports in 2006, 2005, and 
2000, respectively. The mean age was 59.6± 5.1. The most common concurrent 
drugs were corticosteroids (levofloxacin=27.1%, enoxacin=20%, gatifloxacin 
=18.2%, moxifloxacin=14.7%, ciprofloxacin=10.4%, ofloxacin=5.3%, and 
norfloxacin=2.4%). Analysis by the reporting country revealed that most cases 
were reported from the US (70%) followed by Japan (8.2%), Great Britain (3.7%), 
France (.9%) and Canada (.42%). CONCLUSIONS: Tendon rupture was reported 
with most fluoroquinolones. Significant signals existed for all flouroquinolones 
except gemifloxacin, lomefloxacin, and trovafloxacin, which potentially have 
lower risks. However, FAERS data are dependent upon utilization and MedWatch 
reporting rates. As stated in the boxed warning, as stated in the boxed warning, 
concurrent corticosteroids increases risk of tendon rupture  
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OBJECTIVES: The purpose of this study was to investigate the risk of getting 
atrial fibrillation in a year after receiving the first medication and analyze cost-
effectiveness in avoiding the adverse event among alendronate, raloxifene, and 
hormone replacement therapy. METHODS: We used the 2000-2008 National 
Health Insurance Research Database (NHIRD) to identify 10,353 patients who had 
the first medication with drugs and classify them into three groups (7439 
patients defined as those who used alendronate and 2077 patients with 
raloxifene as well as 837 patients with hormone replacement therapy). Cox 
proportional hazard model was used to estimate the hazards of getting atrial 
fibrillation among three drugs. Also, this study used the cost-effectiveness 
analysis to estimate the incremental cost effective ratio in avoiding the adverse 
event as they were treated by different treatments. RESULTS: The Cox regression 
analyses demonstrated that alendronate group (HR=1.52, 95%CI: 0.55-4.19) and 
raloxifene group (HR=1.38, 95%CI: 0.46-4.21) had higher risk in getting atrial 
fibrillation than hormone replacement therapy group, but there were not 
statistically significant. As to the cost-effectiveness analysis in avoiding 1% 
chance of the adverse event, the average medication expenditure of hormone 
replacement therapy group would increase 2,916.7 USD (ICER=2,916.7, 95%CI: 
1063.3–5,102.9) and 2,266.7 USD (ICER=2,266.7, 95%CI: -411.5–5,068.1), comparing 
to alendronate group and raloxifene group respectively. CONCLUSIONS: People 
with osteoporosis that were treated by bisphosphonate or raloxifene are better in 
terms of overall economic cost than those who used hormone replacement 
therapy.  
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OBJECTIVES: Transforaminal Lumbar Interbody Fusion is used to treat 
mechanical back-pain and radicular pain associated with spondylolisthesis due 
to arthritis, herniated disc or spinal stenosis. This procedure is performed either 
in the traditional open technique (o-TLIF) or using minimally invasive (m-TLIF) 
techniques. The goal of this study was to conduct a meta-analysis to compare 
various outcomes when comparing treatments for lumbar spine conditions using 
the “standard” open fusion (o-TLIF) versus minimally invasive surgical fusion (m-
TLIF). METHODS: Prospective and retrospective cohort studies comparing o-TLIF 
to m-TLIF were identified by searching PubMed, EMBASE, the Cochrane libraries, 
and reference lists from selected studies. Of the 15 selected for full-text review, 4 
were excluded because they used the wrong surgical technique, did not include 
m-TLIF, or did not measure the desired outcomes. Effects sizes (relative risks and 
standardized mean differences) were calculated using both fixed- and random-
effects models. RESULTS: Eleven cohort studies (N=554 patients) were included 
in the review (N=259, o-TLIF; and N=294, m-TLIF). Average follow-up ranged from 
12 – 24 months. Random-effects models were used due to the high heterogeneity 
across studies for each outcome (53.1%-93.5%). Use of m-TLIF was associated 
with a 420 mL decrease in blood loss when compared to o-TLIF (standardized 
mean difference (SMD) = -1.57, 95% CI: -2.14 to -0.99, p<0.0001). Operating Room 
(OR) time was significantly longer with a 33 minute increase for those 
undergoing m-TLIF (SMD=0.90, 95% CI: 0.24 to 1.55, p=0.007). CONCLUSIONS: 
While most outcomes did not differ between the two procedures, m-TLIF was 
associated with significantly lower blood loss despite longer OR time. In the 
appropriate clinical population, m-TLIF may be the favorable TLIF procedure for 
treatment of back pain and radicular pain in patients with spondylolisthesis due 
to arthritis, herniated disc or spinal stenosis.  
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OBJECTIVES: Hip resurfacing (HR) was developed for younger, more active 
patients, as a surgical alternative to total hip arthroplasty (THA). The safety of 
metal-on-metal HR is controversial with concerns expressed over adverse events 
and early device failure. We conducted a systematic review comparing primary 
HR to conventional THA for patients with hip osteoarthritis (OA). Outcomes of 
interest were adverse event rates, early failure (revision/reoperation within 5 
years), and post-operative component alignment. METHODS: Studies were 
identified through electronic databases, grey literature and reference lists of 
included studies. Inclusion criteria were: English language studies published 
after 1996 reporting adverse events, complications, safety issues or revision rates 
with respect to adults with primary hip OA, who underwent either primary HR or 
THA. Outcomes of interest included: revision, reoperation, dislocation, 
infection/sepsis, femoral neck fractures, time to revision, rates of early failure, 
mortality, and post-operative component alignment. Results were reported per 
1000 person years for comparability and stratified by age, publication date and 
market status (in-use and discontinued). RESULTS: A total of 7421 abstracts were 
identified and screened. Of these 384 full text articles were reviewed, 236 of 
which were included in this analysis. For all devices, those in-use and 
discontinued, dislocations were more frequent in THA, while revisions and 
reoperations were more frequent in HR. An analysis of only devices currently in-
